1. health and fitness

Rho-Associated Protein Kinase 1 Market Share, Definition,
Treatment, Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated,
Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in
depth analysis on Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, CoiledCoil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted pipeline therapeutics.
The report provides comprehensive information on the Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen
NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1), targeted
therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen
NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted
therapeutics development and features dormant and discontinued projects.
View Full Report with TOC @ http://www.radiantinsights.com/research/rho-associated-protein-kinase-1-renalcarcinoma-antigen-ny-ren-35
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Rho-Associated Protein Kinase 1 (Renal
Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC
2.7.11.1)
- The report reviews Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated,
Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics under development
by companies and universities/research institutes based on information derived from company and industryspecific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35
or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics
and enlists all their major and minor projects
- The report assesses Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated,
Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted therapeutics based on mechanism
of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen
NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) targeted
therapeutics
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand the targeted therapy areas and indications for Rho-Associated Protein Kinase 1 (Renal
Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC
2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rho-Associated Protein Kinase 1 (Renal
Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing Protein Kinase 1 or p160 ROCK-1 or EC
2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/rho-associated-protein-kinase1-renal-carcinoma-antigen-ny-ren-35/request-sample
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) Overview 6
Therapeutics Development 7
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Stage of Development 7
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Therapy Area 8
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Indication 9
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Pipeline Products Glance 10
Early Stage Products 10
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Companies 11
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Products under Development by Universities/Institutes 13
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Rho-Associated Protein Kinase 1 (Renal Carcinoma Antigen NY-REN-35 or Rho-Associated, Coiled-Coil-Containing
Protein Kinase 1 or p160 ROCK-1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 20
Anacor Pharmaceuticals, Inc. 20
View Full Report with TOC @ http://www.radiantinsights.com/research/rho-associated-protein-kinase-1-renalcarcinoma-antigen-ny-ren-35
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: sales@radiantinsights.com
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com